Por: RTTNews Health May 09, 2023
AbbVie () announced Tuesday that Health Canada has approved RINVOQ (upadacitinib, 15 mg), the first oral, once-daily selective and reversible JAK inhibitor for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have had an inadequate response to a biologic disease modifying anti-rheumatic drug (DMARD) or when use of those therapies is inadvisable.This indication... + full article
New York Post USA Life May 19, 2023
Rinvoq is the first oral drug for moderate to severe Crohn’s disease — a chronic intestinal disorder — to be approved by the Food and Drug Administration. There is no cure for Crohn’s disease, and the drug treatments currently available can only help with some level of... + más
AbbVie Says Health Canada Approves RINVOQ To Treat Adults With Active Nr-axSpA | RTTNews
Crohn's disease may be triggered by norovirus infection in people with certain genetic mutations | NBC News
MarketWatch USA Business February 09, 2023
International sales of Humira fell 26.5% from last year as the company lost patent protection in Europe and . However, revenue for the drug that treats Crohn’s disease grew 4.6% globally in the quarter to $5.58 billion, which was slightly above analysts’ estimates. said... + más
How a Drug Company Made $114 Billion by Gaming the U.S. Patent System | The New York Times
Cigna’s PBM Express Scripts Latest To Put Less Pricey Biosimilars Of Abbvie’s Humira On Preferred Drug List | Forbes
The New York Times USA Business January 28, 2023
In 2016, a blockbuster drug called Humira was poised to become a lot less valuable.The key patent on the best-selling anti-inflammatory medication, used to treat conditions like arthritis, was expiring at the end of the year. Regulators had blessed a rival version of the drug,... + más
Will More Women Patent Attorneys Lead To More Women Inventors? | Forbes
Samsung Beats IBM, Apple, Intel, Google For 2022 Patent Crown; 56% Of U.S. Patents Go To Foreign Firms | Forbes
MarketWatch USA Business January 22, 2023
A few weeks later, in December, the biotechnology company BeiGene stole the show at the American Society of Hematology’s big annual meeting in New Orleans. BeiGene showing its Btk inhibitor pill, Brukinsa, beating Imbruvica on efficacy and safety in a trial of CLL patients. ... + más
Shaikin: Baseball embracing the 'flukes' and plenty of added revenue this postseason | Los Angeles Times
Watch the wreck of the Brookhill ferry return to the waters of the Mississippi River | The Advocate
MarketWatch USA Politics December 27, 2022
The worst may be over for the stock market for this cycle, but many economists see more pain ahead for 2023, including a possible recession that will create poor financial-performance comparisons for companies and send stock prices even lower. Greg Adams, director of... + más
What Are the Duties of A Trustee? | Forbes
The 'Friday the 13th' series includes 12 horror movies — here's where to watch them all this Halloween season | Business Insider
Forbes USA Tech December 05, 2022
Cigna’s pharmacy benefit manager Express Scripts will put “multiple biosimilar versions of Abbvie’s ... [+] expensive rheumatoid arthritis drug Humira in the “same position as the brand” on the PBM’s as a formulary in 2023. AbbVie's signature drug Humira is... + más
Cigna received millions of Medicare dollars based on invalid diagnoses, lawsuit claims | ABC News
How To Get Away With Corporate Murder: Unbundling And Disrupting Pharmacy Benefit Managers (Part 2) | Forbes
RTTNews USA Health October 28, 2022
AbbVie () announced Friday that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody, for the treatment of adult patients with relapsed/refractory... + más
Don’t Pay for Cord-Blood Banking | The Atlantic
Prime Video’s Aparna Purohit Reveals How Madhuri Dixit Got Onboard For ‘Maja Ma’ | Forbes
About iurex | Privacy Policy | Disclaimer |